Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. [electronic resource]
- Science signaling Aug 2013
- ra68 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't